Subtype
Malignant Pharyngeal Neoplasm
CI-CAN-00003219Explore in graph →
411 active trials1 approved drugs2 evidence items
- NCIt
- C7545
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003219Explore in graph →
Clinical trials
1,255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (112)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)(CompARE) | active not recruiting | Phase 3 | 785 | University of BirminghamOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT05201859 | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05524168 | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07311772 | Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03848286 | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 153 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05600842 | De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx | recruiting | — | 111 | University of California, IrvineOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07013461 | International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer | recruiting | — | 5,000 | The University of Hong Kong-Shenzhen HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma(AK112) | not yet recruiting | Phase 2 | 42 | National University Hospital, SingaporeOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 188 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05531916 | Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial(CIPN) | active not recruiting | N/A | 182 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05714657 | Shortened Course Adjuvant Radiotherapy Following TORS | active not recruiting | Phase 2 | 104 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT04564989 | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | recruiting | — | 220 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552883 | Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis(EPoRN) | not yet recruiting | N/A | 40 | Jiangxi Provincial Cancer HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT02633202 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | completed | Phase 3 | 338 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06706401 | Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma(LYSARI) | recruiting | Phase 3 | 460 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05491512 | A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer | recruiting | Phase 2 | 121 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548268 | Transoral and Cervical Ultrasound of Patients With Suspected Oropharyngeal Cancer | recruiting | N/A | 180 | Tobias TodsenOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06356272 | Oropharynx (OPX) Biomarker Trial | recruiting | — | 560 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | not yet recruiting | Phase 3 | 442 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03621696 | Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"(MINT) | completed | Phase 2 | 63 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | active not recruiting | Phase 3 | 386 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06902623 | Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy(Lombardi197) | recruiting | N/A | 30 | Georgetown UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03010150 | Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer | recruiting | — | 471 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04870762 | Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | recruiting | Phase 2 | 119 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06093061 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 53 | National Cancer Centre, SingaporeOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07496190 | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy | recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05563480 | TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 47 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05483374 | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers(EURACAN) | recruiting | — | 13,600 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 3 | Apr 3, 2026 | clinicaltrials |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05587543 | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma | recruiting | Early Phase 1 | 24 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06554158 | De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers | recruiting | N/A | 30 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 7, 2026source: clinicaltrials